FibroGen to Present at Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SAN FRANCISCO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced CEO Enrique Conterno will participate in fireside chats at two upcoming healthcare conferences:
- Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 1:20 PM ET
- Jefferies Virtual London Healthcare Conference on November 19, 2020, at 12:35 PM ET
Live webcasts will be available on FibroGen's Investor webpage, with replays accessible for 30 days. FibroGen focuses on developing therapeutics for unmet medical needs, including treatments for anemia and idiopathic pulmonary fibrosis.
Details
News Market Reaction – FGEN
The recorded move for FGEN in the trading session of this news was -2.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following healthcare conferences:
- Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 1:20 PM Eastern Time
- Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 12:35 PM Eastern Time
A live audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at https://fibrogen.gcs-web.com/. A replay will be available for approximately 30 days.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19). For more information, please visit www.fibrogen.com.
Contact:
FibroGen, Inc.
Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
1.415.630.0131
mtung@fibrogen.com
Media:
Jennifer Harrington
+1.610.574.9196
Jennifer.Harrington@gcihealth.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.